Clinical Trials Logo

Bladder Neoplasms clinical trials

View clinical trials related to Bladder Neoplasms.

Filter by:

NCT ID: NCT05072600 Recruiting - Bladder Cancer Clinical Trials

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.

NCT ID: NCT02900248 Terminated - Multiple Myeloma Clinical Trials

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

N1
Start date: October 2, 2017
Phase:
Study type: Observational [Patient Registry]

Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to meet a high quality standard. Treatments and outcomes will be reported to the registry to allow further understanding of how genetic differences can lead to better diagnosis and treatments.

NCT ID: NCT01090388 Completed - Bladder Neoplasms Clinical Trials

Bladder Cancer Patient-Reported Outcomes

Start date: July 2007
Phase: N/A
Study type: Observational

The purpose of this study is to identify aspects of the bladder cancer (BlCa) survivorship experience that differ by clinical risk at diagnosis. The investigators will collect cross-sectional data from persons with BlCa to identify aspects of health-related quality of life (HRQOL) and symptom management. The study originally enrolled only nonmuscle-invasive bladder cancer survivors but has been expanded to include survivors with any stage disease. Information from this study will be used to develop a new patient education and counseling intervention.

NCT ID: NCT00963404 Completed - Bladder Neoplasms Clinical Trials

Image-Guided Tumorboost of Bladder Cancer

Start date: August 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to increase the radiation dose (Boost) to the bladder tumor. The bladder cancer patients included in the study will undergo tumor demarcation. The bladder demarcations will then be the target for an image-guided boost delivered precisely to the expected tumor site.

NCT ID: NCT00872495 Recruiting - Cancer Clinical Trials

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

Start date: September 2002
Phase:
Study type: Observational

The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bladder and kidney. This analysis may be helpful to determine if how a particular cancer will act regarding remission and recurrence

NCT ID: NCT00871754 Active, not recruiting - Bladder Cancer Clinical Trials

Molecular Analysis Of Bladder Cancer

Start date: April 1988
Phase:
Study type: Observational

This is a laboratory study where the investigators hope to look at chromosomal events implicated in bladder cancer.

NCT ID: NCT00536588 Completed - Bladder Neoplasms Clinical Trials

A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)

Start date: September 2006
Phase: Phase 1
Study type: Interventional

The purpose of this first-in-human study is to determine the safety and tolerability of SCH 721015 in subjects with transitional cell carcinoma of the bladder.

NCT ID: NCT00491114 Completed - Bladder Neoplasms Clinical Trials

Intravesical Chemotherapy Treatment of Superficial Bladder Cancer

Start date: July 2003
Phase: Phase 2
Study type: Interventional

This is a phase II study where chemotherapy (gemcitabine) is given into the urinary bladder.

NCT ID: NCT00462488 Completed - Bladder Cancer Clinical Trials

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).

NCT ID: NCT00406068 Completed - Bladder Neoplasms Clinical Trials

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Start date: November 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional cell carcinoma (papillary tumors and/or carcinoma in situ) of the urinary bladder at high risk of progression who are refractory to therapy with bacillus Calmette-Guerin (BCG).